Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 1/2011

01-02-2011

Prostate Cancer Screening

Authors: Elise D. Cook, Ana C. Nelson

Published in: Current Oncology Reports | Issue 1/2011

Login to get access

Abstract

Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. Although the use of the prostate-specific antigen (PSA) test for prostate cancer screening since the 1990s has led to increased early diagnoses, the most recent studies are in conflict about the risks and benefits of routine prostate cancer screening. Recently, evidence has emerged to support the use of the PSA test to lower mortality, but there is still concern that over-diagnosis may lead to over-treatment of cancers that would not significantly affect patients’ health for several years. This article describes the results of important recent prostate cancer screening trials, the National Comprehensive Cancer Network and American Cancer Society screening guidelines, and discusses the implications for clinical practice.
Literature
1.
•• Hugosson J, Carlsson S, Aus G, et al.: Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725–732. The Goteborg study’s first report on cumulative prostate cancer incidence and mortality demonstrated a significant reduction in prostate cancer mortality over a 14-year period, and the benefit of prostate cancer screening compared favorably to that of other cancer screenings. CrossRefPubMed
2.
•• Schroder FH, Hugosson J, Roobol MJ, et al.: Screening and prostate-cancer mortality in a randomized European study. N Eng J Med 2009, 360:1320–1328. Data from the ERSPC trial showed that PSA-based screening decreased the prostate cancer-related mortality rate by 20%. CrossRef
3.
4.
5.
Catalona WJ, Smith DS, Ratliff TL, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med 1991, 324:1156–1161.CrossRef
6.
Wolf A, Wender RC, Etzioni RB, et al.: American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010. CA Cancer J Clin 2010, 60:70–98.CrossRefPubMed
7.
8.
Mills GB, Reiger PT: Genetic predisposition to breast cancer. In Breast Cancer. Edited by Hunt KK, Robb GL, Strom EA, Ueno NT. New York: Springer-Verlag; 2001:55–82.
9.
Thompson IM, Ankerst DP, Chi C, et al.: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98:529–534.CrossRefPubMed
10.
•• Andriole, GL, Crawford ED, Grubb RL, et al.: Mortality results from a randomized prostate-cancer screening trial. N Eng J Med 2009, 360:1310–1319. The PLCO cancer screening trial in the United States did not demonstrate a statistically significant reduction in prostate cancer-related mortality in men randomized to receive PSA and DRE screening. CrossRef
11.
Esserman L, Shieh Y, Thompson I: Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302:1685–1692.CrossRefPubMed
12.
Draisma G, Etzioni R, Tsodikov A, et al.: Lead time and over-diagnosis in prostate-specific antigen screening: importance of methods of context. J Natl Cancer Inst 2009, 101:374–383.CrossRefPubMed
13.
Hakama M, Coleman MP, Alexe DM, Auvinen A: Cancer screening: evidence and practice in Europe 2008. Eur J Cancer 2008, 44:1404–1413.CrossRefPubMed
14.
Essink-Bot ML, de Koning HJ, Nijs HG, et al.: Short term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998, 90:925–931.CrossRefPubMed
15.
Fowler FJ Jr, Barry MJ, Walker-Corkery B, et al.: The impact of suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med 2006, 21:715–721.CrossRefPubMed
16.
Roberts RO, Bergstralh EJ, Besse JA, et al.: Trends and risk factors for biopsy complications in the pre-PSA and PSA eras, 1980 to 1997. Urology 2002, 59:79–84.CrossRefPubMed
17.
Djavan B, Zlotta A, Remzi M, et al.: Optimal predictors of cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000, 163:1144–1148; discussion 1148–1149.CrossRefPubMed
18.
Hu JC, Gu Xiangmei GU, Lipsitz SR, et al.: Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009, 302:1557–1564.CrossRefPubMed
19.
Elliot SP, Meng MV, Elkin EP, et al.: Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE. J Urol 2007, 178:529–534; discussion 534.CrossRef
20.
21.
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection v.2.2010. Available at http://​www.​nccn.​org. Accessed August 5, 2010.
22.
Eyre SJ, Ankerst DP, Wei JT, et al.: Validation in a multiple urology practice cohort of Prostate Cancer Prevention Trial calculator for predicting cancer detection. J Urol 2009, 182:2653–2658.CrossRefPubMed
23.
Parekh DJ, Ankerst DP, Higgins BA, et al.: External validation of the Cancer Prevention Trial risk calculator in screened population. Urology 2006, 68:1152–1155.CrossRefPubMed
24.
Ankerst DP, Groskopt J, Day JR, et al.: Predicting prostate cancer risk through incorporation of cancer gene 3. J Urol 2008, 180:1303–1308; discussion 1308. CrossRefPubMed
25.
Carter HB, Pearson JD, Metter EJ, et al.: Longitudinal evaluation of prostate-specific antigen levels in men with and without disease. JAMA 1992, 267:2215–2220.CrossRefPubMed
26.
Carter HB, Ferrucci L, Kettermann A, et al.: Detection of life-threatening cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006, 98:1521–1527.CrossRefPubMed
Metadata
Title
Prostate Cancer Screening
Authors
Elise D. Cook
Ana C. Nelson
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 1/2011
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0136-x

Other articles of this Issue 1/2011

Current Oncology Reports 1/2011 Go to the issue

ReviewPaper

Denosumab in Breast Cancer

ReviewPaper

Breast Cancer Screening with Mammography

ReviewPaper

The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?

ReviewPaper

Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment

ReviewPaper

Patient Profiling for Treatment Toxicity: Potential Use of Clinical and Genomic Factors

ReviewPaper

Response Assessment in Neuro-Oncology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits